FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.,Journal of Clinical Oncology

当前位置： X-MOL 学术 › J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2024-05-29 , DOI: 10.1200/jco.2024.42.16_suppl.tps2702
Jonas S. Heitmann ₁ , Michael Bitzer ₂ , Christopher Hackenbruch ₁ , Jens Bauer ₃ , Yacine Maringer ₃ , Annika Nelde ₃ , Helmut R. Salih ₄ , Juliane S. Walz ₅

Affiliation

Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page TPS2702-TPS2702, June 2024.

中文翻译：

FusionVAC22_01：一项 I 期临床试验，评估基于 DNAJB1-PRKACA 融合转录物的肽疫苗与免疫检查点抑制相结合，用于纤维板层肝细胞癌和其他携带致癌驱动融合的肿瘤实体。

《临床肿瘤学杂志》，第 42 卷，第 16 期_suppl，TPS2702-TPS2702 页，2024 年 6 月。

更新日期：2024-05-30

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南